It has recently been shown that nanoparticle albumin-bound paclitaxel (nab-PAC)+carboplatin (CBDCA) provides a favorable overall response rate in non-small cell lung cancer. This is the first case report of nab-PAC+CBDCA therapy in small cell lung cancer (SCLC). Our patient was a 72-year-old man with stage IV SCLC combined with squamous cell carcinoma and interstitial lung disease (ILD). We administered nab-PAC+CBDCA as a second-line chemotherapy. A partial response was evident after two cycles of chemotherapy, and no serious side effects occurred. The progression-free survival was 15 weeks. Second-line chemotherapy using nab-PAC+CBDCA was effective and well tolerated in an SCLC patient with ILD.
Introduction
The risk of fatal pneumonitis is a substantial obstacle in the treatment of small cell lung cancer (SCLC) with interstitial lung disease (ILD). Topotecan or paclitaxel can be used as a second-line treatment for such patients; however, previously treated patients have few treatment options in Japan (1) . Relatively recently, nanoparticle albumin-bound paclitaxel (nab-PAC) was introduced for non-small cell lung cancer (NSCLC) therapy. In a study of NSCLC, the overall response rate for nab-PAC+carboplatin (CBDCA) was demonstrated to be significantly better than that for solventbased paclitaxel (sb-PAC)+CBDCA, especially among patients with squamous cell carcinoma (2) . Consequently, nab-PAC+CBDCA is considered to be one of the standard regimens for squamous cell carcinoma. However, no studies concerning the use of this regimen for SCLC have yet been reported. We herein report the first case of SCLC and ILD treated with nab-PAC+CBDCA as a second-line chemotherapy.
Case Report
A 72-year-old male ex-smoker (68 pack years) of Japanese descent presented at our hospital with ILD. The patient had a cough, and a chest computed tomography scan showed a mass in the inferior lobe of the right lung and ILD with usual interstitial pneumonia (UIP) in both the inferior lobes. He was diagnosed with stage IV SCLC (T2aN2M 1b) combined with squamous cell carcinoma ( Fig. 1 ) and brain metastasis. His performance status was one, and he showed no symptoms associated with the brain metastasis. Etoposide+cisplatin chemotherapy was selected as a firstline therapy. The primary lesion increased in size and small cell cancer markers (pro-gastrin-releasing peptide and neuron-specific enolase) were elevated after three treatment cycles. Therefore, the cancer was judged to be progressive. As we had diagnosed combined SCLC and squamous cell carcinoma in this case, we judged that the use of nab-PAC was acceptable. We chose nab-PAC (100 mg/m 2 )+CBDCA (area under the curve = five) as a second-line therapy and the patient provided written informed consent before treat- A B ment. Nab-PAC was administered on days one and 15 every four weeks. During the first cycle, grade 4 neutropenia appeared, but was cured soon thereafter using granulocyte colony-stimulating factor. The patient did not develop febrile neutropenia. Acute exacerbation of ILD and unknown side effects were not observed in the patient. After two treatment cycles, a partial response was evident. The primary lesion had significantly decreased in size (Fig. 2) , and symptoms improved. Therapy was continued for two more cycles, after which the disease was judged to be progressive because the pulmonary metastasis had grown, and the treatment regimen was thus stopped. Ultimately, the progression-free survival was 15 weeks.
Discussion
SCLC is chemosensitive; most patients relapse and require a second-line treatment (3) . Furthermore, SCLC patients are prescribed amrubicin, irinotecan or topotecan as a second-line therapy. However, amrubicin and irinotecan are contraindicated for ILD, so we instead usually administer topotecan or sb-PAC+CBDCA to patients with ILD. Treatment with sb-PAC+CBDCA is effective for relapsed SCLC (response rate 73.5%) (4).
In the current case, nab-PAC+CBDCA was selected for two reasons. First, nab-PAC has a lower toxicity than sb-PAC. PAC is poorly soluble in water, and sb-PAC contains the non-ionic solvent Cremophor EL (BASF, Ludwigshafen am Rhein, Germany). This solvent improves the solubility of PAC and thus makes intravenous injection possible. However, Cremophor EL increases hypersensitivity (5). Nab-PAC is a novel solvent-free formulation of PAC, which allows safer and faster infusions without premedication to prevent hypersensitivity (6) . Second, nab-PAC+CBDCA has been found to be more effective than sb-PAC+CBDCA for NSCLC, especially for squamous cell carcinoma. Nab-PAC+ CBDCA demonstrated a significantly higher overall response rate, and a relatively better overall survival and progression-free survival than sb-PAC+CBDCA (2). We presumed that the results for SCLC could be similar. Indeed, the progression-free survival was 15 weeks in our case, thus providing a tentative and preliminary indication that nab-PAC+CBDCA is not inferior to other regimens as a secondline chemotherapy for SCLC.
SCLC with ILD has a poor prognosis. In particular, the overall survival in SCLC patients with a UIP pattern is significantly shorter than in patients with a non-UIP pattern (7) . At present, we have few treatment options for SCLC with ILD, and therefore, it is still necessary to discover a new treatment for this disease. This is the first report that describes the use of nab-PAC+ CBDCA for SCLC in a patient with ILD. In this case, we observed that the nab-PAC+CBDCA regimen had relatively good results and tolerability as a second-line chemotherapy. Accordingly, further investigations of this regimen are required for patients with SCLC and ILD.
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